The Complement System and Its Role and Function in Immunology

The immune system of vertebrates is composed of a complex network of cells, molecules, and pathways designed to recognize and neutralize potentially harmful agents while preserving the integrity of host tissues. A central feature of this defence is the ability to mount both innate and adaptive responses. Within innate immunity, the complement system occupies a unique and indispensable place. It is one of the most ancient and evolutionarily conserved components of host defence systems, consisting of a cascade of soluble plasma proteins that interact in a highly regulated manner to eliminate pathogens, orchestrate inflammation, and modulate the activity of adaptive immune mechanisms.

The complement system was first described in the late 19th century, when Jules Bordet identified a heat-labile serum factor that “complemented” the action of antibodies in killing bacteria. Since then, complement has been recognized not merely as a passive adjunct to antibody-mediated immunity but as a sophisticated system in its own right, with diverse effector and regulatory functions. In humans, more than 30 soluble and membrane-bound proteins form the complement network, many of which circulate as inactive precursors until triggered by pathogen-associated or immune-complex-associated signals.

This article provides a comprehensive discussion of the complement system, beginning with its structure and activation pathways, moving through its effector functions, and concluding with its regulatory mechanisms and roles in health and disease. Throughout, the complement system is presented as a dynamic bridge between innate and adaptive immunity, illustrating its centrality in the overall architecture of host defence.

---

The Structure of the Complement System

Complement proteins are mainly synthesized in the liver, though some immune cells and epithelial cells also produce complement locally. In plasma, these proteins exist in an inactive or zymogen state, poised to respond rapidly upon activation. The cascade is organized such that cleavage of one protein generates enzymatically active fragments, which then act on subsequent components, amplifying the response in a domino-like fashion.

Key proteins include C1 through C9, as well as numerous regulatory molecules such as factor H, factor I, C1 inhibitor (C1-INH), decay-accelerating factor (DAF), and CD59. Collectively, these molecules mediate recognition of danger, amplification of response, formation of enzymatic complexes, generation of potent effector molecules, and termination of activity to prevent damage to self-tissues.

---

Complement Activation Pathways

The complement pathway is activated by recognition of bacterial surfaces. Complement activation can occur via three main pathways: the classical pathway, the lectin pathway, and the alternative pathway. Although they differ in initiation, all three converge at the activation of C3, the central component of complement, and ultimately lead to the formation of the membrane attack complex (MAC).

1. The Classical Pathway
The classical pathway is typically triggered by antigen–antibody complexes. The C1 complex, composed of C1q, C1r, and C1s subunits, recognizes and binds to the Fc regions of antibodies (IgM or IgG) bound to antigen. This activates C1r and C1s, which cleave C4 and C2 to generate the C4b2a complex, known as the classical C3 convertase. This enzyme cleaves C3 into C3a and C3b, launching the amplification cascade.

2. The Lectin Pathway
The lectin pathway shares similarity with the classical pathway but is initiated by recognition of specific carbohydrate patterns on microbial surfaces. Mannose-binding lectin (MBL) or ficolins bind to mannose or N-acetylglucosamine residues on bacteria, fungi, or viruses. MBL-associated serine proteases (MASPs) then cleave C4 and C2, forming the same C3 convertase (C4b2a) as in the classical pathway. This pathway highlights complement’s role in innate recognition independent of antibodies.

3. The Alternative Pathway
The alternative pathway provides constant low-level surveillance of host and microbial surfaces. It is initiated by the spontaneous hydrolysis of C3 into C3(H2O), which can bind factor B. Factor D cleaves factor B into Bb, forming the fluid-phase C3 convertase C3(H2O)Bb. On pathogen surfaces lacking regulatory proteins, C3b generated by any pathway can also bind factor B to form the surface-bound C3bBb complex, the alternative pathway C3 convertase. This convertase is stabilized by properdin, enhancing amplification. The alternative pathway thus provides an immediate response to pathogens even in the absence of antibodies or lectins.

All three pathways converge at C3 cleavage. The resulting C3b molecules covalently attach to nearby surfaces, acting both as opsonins and as participants in the formation of C5 convertases. The C5 convertases cleave C5 into C5a, a potent anaphylatoxin, and C5b, which initiates assembly of the terminal pathway and formation of the MAC (C5b-9).

---

Effector Functions of Complement

Complement activation produces a range of effector molecules that mediate diverse functions in immunity.

1. Opsonization
C3b and its cleavage products (iC3b, C3dg) covalently attach to microbial surfaces and function as opsonins, enhancing phagocytosis. Phagocytic cells such as macrophages and neutrophils express complement receptors (e.g., CR1, CR3, CR4) that recognize C3 fragments. Opsonization dramatically increases the efficiency of pathogen clearance compared to phagocytosis without complement.

2. Chemotaxis and Inflammation
Complement fragments C3a, C4a, and particularly C5a act as anaphylatoxins. They bind to receptors on mast cells, basophils, and endothelial cells, inducing degranulation, increased vascular permeability, and smooth muscle contraction. C5a is also a powerful chemoattractant, recruiting neutrophils and monocytes to sites of infection. This role links complement activation directly to inflammation and cellular immune responses.

3. Direct Cytolysis
The terminal pathway culminates in the formation of the membrane attack complex (MAC). C5b initiates sequential assembly with C6, C7, C8, and multiple copies of C9, forming a pore in the target cell membrane. This pore disrupts osmotic balance, leading to lysis of susceptible pathogens, particularly Gram-negative bacteria. While MAC-mediated lysis is less effective against Gram-positive bacteria or eukaryotic cells due to thicker cell walls or protective mechanisms, it remains an important effector function.

4. Clearance of Immune Complexes and Apoptotic Cells
Complement plays a critical role in clearing immune complexes from circulation. C3b binds to immune complexes, facilitating their solubilization and transport to the liver and spleen, where they are removed by phagocytes. Similarly, complement opsonizes apoptotic cells, marking them for safe clearance and preventing secondary necrosis and inflammation.

5. Bridging Innate and Adaptive Immunity
Complement also influences adaptive immune responses. Complement receptor 2 (CR2, or CD21) on B cells binds C3d fragments, lowering the threshold for B cell activation and enhancing antibody responses. Complement activation thus not only fights infection directly but also shapes the quality and magnitude of adaptive immunity.

---

Regulation of Complement Activity

Given its powerful effector functions, the complement system must be tightly regulated to prevent damage to host tissues. Multiple soluble and membrane-bound regulators ensure that complement activity is targeted toward pathogens rather than self.

• C1 inhibitor (C1-INH): Inhibits C1r and C1s, preventing spontaneous activation of the classical pathway.

• Factor H and Factor I: Work together to inactivate C3b by cleaving it into iC3b, reducing alternative pathway amplification. Factor H also competes with factor B for C3b binding.

• Decay-accelerating factor (DAF, CD55): Found on host cell membranes, it accelerates the dissociation of C3/C5 convertases, preventing sustained activation.

• CD59 (protectin): Inhibits the incorporation of C9 into the MAC, protecting host cell membranes from lysis.

• Membrane cofactor protein (MCP, CD46): Serves as a cofactor for factor I-mediated cleavage of C3b and C4b on host cells.

These regulators ensure that complement activation is localized and self-limiting. Failure of regulation leads to autoimmune pathology or excessive inflammation.

---

Complement in Host Defense

Complement is indispensable for host defense against microbial infection. Individuals with congenital deficiencies in complement components often exhibit severe susceptibility to infection, illustrating its importance. For example:

• Deficiencies in C3 result in recurrent pyogenic infections due to impaired opsonization.

• Deficiencies in terminal pathway components (C5–C9) predispose individuals to recurrent Neisseria infections, highlighting the importance of MAC-mediated killing for these bacteria.

• Deficiencies in regulatory proteins, such as factor H or factor I, lead to uncontrolled complement activation and damage to host tissues, contributing to conditions such as atypical hemolytic uremic syndrome (aHUS).

Thus, complement serves as a vital first line of defense, particularly in the early stages of infection before adaptive immunity is fully engaged.

---

Complement in Inflammation and Disease

While complement protects against infection, dysregulated activation contributes to a range of inflammatory and autoimmune diseases.

Autoimmunity and Immune Complex Disease:
In systemic lupus erythematosus (SLE), defective clearance of immune complexes and apoptotic cells due to complement deficiency contributes to chronic inflammation and autoantibody production. Low complement levels (C3, C4) are commonly used as biomarkers in SLE diagnosis and monitoring.

Inflammatory Tissue Damage:
Complement contributes to pathology in diseases such as rheumatoid arthritis and ischemia-reperfusion injury, where excessive complement activation amplifies tissue damage.

Paroxysmal Nocturnal Hemoglobinuria (PNH):
A rare acquired disorder caused by deficiency of DAF (CD55) and CD59 on red blood cells due to mutations in the PIGA gene. Without these regulators, complement-mediated lysis of red blood cells occurs, leading to hemolysis and anemia.

Age-related Macular Degeneration (AMD):
Dysregulation of the alternative pathway, particularly mutations in factor H, is strongly associated with AMD, a leading cause of blindness in the elderly.

These examples illustrate the dual nature of complement: protective in normal function, destructive when uncontrolled.

---

Complement as a Therapeutic Target

The recognition of complement’s role in disease has spurred development of therapeutic strategies aimed at modulating its activity. Several complement inhibitors are now in clinical use or under investigation:

• Eculizumab: A monoclonal antibody against C5, preventing formation of C5a and MAC. It is used in treating PNH and aHUS.

• C1-INH replacement therapy: Used in hereditary angioedema, a condition caused by C1-INH deficiency leading to uncontrolled bradykinin production and swelling.

• Factor D inhibitors: Investigated for treatment of AMD by suppressing the alternative pathway.

These therapeutics highlight the clinical importance of understanding complement regulation and function.

---

Complement and Emerging Perspectives

Recent research has revealed additional roles for complement beyond traditional immunity. Complement proteins are expressed not only in plasma but also locally in tissues such as the brain, kidney, and placenta, where they contribute to homeostasis and pathology.

In the central nervous system, complement mediates synaptic pruning during development, guiding the maturation of neural circuits. Dysregulated complement activity in the brain has been implicated in neurodegenerative diseases such as Alzheimer’s disease, where complement-mediated clearance of synapses may exacerbate cognitive decline.

In cancer biology, complement plays paradoxical roles. On one hand, complement activation can promote anti-tumor immunity by enhancing immune recognition. On the other hand, chronic complement activation can foster a pro-inflammatory microenvironment that supports tumor growth and metastasis. Therapeutic manipulation of complement in oncology is therefore a growing field.

These findings broaden our understanding of complement from a pathogen defense system to a versatile mediator of tissue homeostasis, development, and pathology.

---

Complement as a Bridge Between Innate and Adaptive Immunity

One of the most significant features of complement is its ability to integrate innate and adaptive immunity. While it originates as an innate surveillance system, complement influences adaptive responses in several ways:

• B cell activation: Binding of complement fragments such as C3d to antigen enhances B cell receptor signaling via CR2/CD21, promoting antibody production.

• T cell modulation: Complement fragments influence T cell differentiation and survival, with evidence that C3a and C5a signaling can shape Th1/Th17 responses.

• Antigen presentation: Complement opsonization facilitates uptake of antigens by antigen-presenting cells, improving antigen processing and presentation to T cells.

These interactions illustrate how complement amplifies and fine-tunes adaptive immunity, demonstrating its central role as a bridge between innate recognition and adaptive specificity.

---

This I hope is a clear summary table of the complement pathways showing their initiators, convertases, and main outcomes:

---

---

Shared terminal pathway (all three):

• C5b recruits C6, C7, C8, and multiple C9 molecules → forms Membrane Attack Complex (MAC, C5b-9) → lysis of susceptible microbes.

Conclusion

The complement system is one of the most versatile and powerful components of the immune system. Composed of more than 30 proteins and regulatory molecules, it is capable of recognizing diverse danger signals, amplifying responses through enzymatic cascades, and deploying potent effector mechanisms including opsonization, inflammation, and direct cytolysis. Its regulation is equally sophisticated, ensuring that these defenses are directed against pathogens while sparing host tissues.

Functionally, complement is indispensable for resistance to infection, but its influence extends far beyond pathogen elimination. It clears immune complexes and apoptotic debris, shapes adaptive immune responses, and participates in processes as diverse as neural development and tumor progression. The double-edged nature of complement is evident in diseases ranging from autoimmunity to hemolysis and age-related degeneration, highlighting the delicate balance between protection and pathology.

Therapeutically, complement represents an exciting frontier. Advances in complement inhibitors have already transformed treatment of rare but devastating diseases, and ongoing research promises new interventions for common conditions such as AMD, Alzheimer’s disease, and cancer.

From its historical discovery as a mysterious “complementary” factor to antibodies, to its modern recognition as a multifunctional immune sentinel, the complement system exemplifies the elegance and complexity of host defense. Its study continues to illuminate not only the mechanisms of immunity but also the intricate interplay between biology, disease, and therapy.